{
  "authors": [
    {
      "author": "Katherine Linder"
    },
    {
      "author": "Deepthi Gandhiraj"
    },
    {
      "author": "Madhura Hanmantgad"
    },
    {
      "author": "Karen Seiter"
    },
    {
      "author": "Delong Liu"
    }
  ],
  "doi": "10.1186/s40164-016-0051-4",
  "publication_date": "2015-01-01",
  "id": "EN115516",
  "url": "https://pubmed.ncbi.nlm.nih.gov/27468365",
  "source": "Experimental hematology & oncology",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens."
}